Devices/Safety Alert·openFDA/device

FREESTYLE LIBRE 3 PLUS (ABBOTT DIABETES CARE INC) — Malfunction

MediumPublished Apr 30, 2026· AI-analyzed May 19, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

A malfunction event was reported regarding the FreeStyle Libre 3 Plus device manufactured by Abbott Diabetes Care Inc. and documented in the FDA database on April 30, 2026.

Who it affects

The manufacturer, Abbott Diabetes Care Inc., and regulatory/quality professionals responsible for the oversight of continuous glucose monitoring systems.

Why it matters

The reporting of a malfunction suggests a deviation from the device's intended performance specifications. While the source does not provide specific technical details or the root cause, such reports are a critical component of the FDA's post-market surveillance. Regulatory teams may need to assess whether this indicates a recurring technical issue requiring CAPA or localized performance variance.

Practical takeaway

Regulatory and QA teams should review internal malfunction reporting thresholds for continuous glucose monitors. Ensure post-market surveillance workflows are capturing similar performance deviations to maintain compliance with adverse event reporting requirements.

FDA source material

Event type: Malfunction. Device: FREESTYLE LIBRE 3 PLUS by ABBOTT DIABETES CARE INC.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.